Fifty1 Labs Partners with LUNR Aerospace to Pioneer AI-Driven Drug Repurposing for Space Medicine, Strategic Collaboration Aims to Harness AI and Orbital Access to Revolutionize Astronaut Health Solutions in a $2 Billion Market by 2032

VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- via IBN --  Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), has entered a groundbreaking partnership with LUNR Aerospace to develop AI-driven drug repurposing initiatives tailored for space medicine. This collaboration targets critical health challenges in microgravity, including immune support, musculoskeletal resilience, neuro-ocular protection (Spaceflight-Associated Neuro-Ocular Syndrome, or SANS), cardiovascular stability, cognitive performance, sleep optimization, and metabolic longevity, addressing the unique physiological demands of space exploration.